The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab
Open accessAbstract
Alzheimer’s disease (AD) is the most prevalent form of age-related dementia in the world, and its main pathological features consist of amyloid-β (Aβ) plaque deposits and neurofibrillary tangles formed by hyperphosphorylated tau protein. So far, only a few AD treatments approved have been applied in the clinic, but the effects of these drugs are limited only for partial symptomatic relief to patients with AD and are unable to alter AD progression. Later, all efforts for AD treatments with targeting the pathogenic factors were unsuccessful over the past decades, which suggested that the pathogenesis of AD is complex. Recently, disease-modifying therapies (DMTs) that can change the underlying pathophysiology of AD, with anti-Aβ monoclonal antibodies (mabs) (e.g., aducanumab, bapineuzumab, gantenerumab, solanezumab, and lecanemab) have been developed successively and conducted in clinical trials based on the theory that a systemic failure of cell-mediated Aβ clearance contributes to AD occurrence and progression. In the review, we summarized recent studies on the therapeutic effects and clinical trial results of these mabs in patients with AD. Specifically, we focused on the discussion of the impact of aducanumab and lecanemab on AD pathology and clinical profiles. The review provides a possible evidence for applying immunotherapy with anti-Aβ mabs in AD and analyzes lessons learned from these clinical trials in order to further study the therapeutic and adverse effects of these anti-Aβ mabs on AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Recent therapies targeting Aβ clearance using anti-Aβ monoclonal antibodies (mabs) during the early stages of AD provide minimal cognitive benefit”
From Perineuronal net deglycosylation associates with tauopathy‐induced gliosis and neurodegeneration (2024) · cites this paper as Shi et al. 2022
In the citing paper
“Studies have shown that Aβ buildup can start 15–20 years before clinical symptoms appear, indicating that therapy effectiveness may depend on early intervention [88,89].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [89]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus [RETIRED]
Day, G. S., Scarmeas, N., Dubinsky, R., Coerver, K., Mostacero, A., West, B., Wessels, S. R., & Armstrong, M. J. (2022) · Neurology · doi:10.1212/wnl.0000000000200176 · Cited by 42
RetractedClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Research works printed but not linked: 3
- 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer’s Disease (ENGAGE).
- 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer’s Disease (EMERGE).
- Swanson, 2018, Clinical and biomarker updates from BAN2401 Study 201 in early AD, Proceedings of Clinical Trials on Alzheimer’s Disease Conference
Cited by
Sorted by citations
Items 201–277 of 277
Kodishala, C., George, R. J., Javed, R., Lovering, E., Crowson, C. S., Lennon, R. J., Hulshizer, C. A., & Myasoedova, E. (2025) · Scandinavian Journal of Rheumatology · doi:10.1080/03009742.2025.2503055 · Cited by 1
Effectiveness of Lecanemab on Alzheimer’s Disease
Thomas, F. J., Khan, M. A. Q. S., Khan, R. A., & Patel, S. V. (2024) · Precision Nanomedicine · doi:10.33218/001c.92098 · Cited by 1
Tekin, E., Küçük, A., & Arslan, M. (2024) · Gazi Medical Journal · doi:10.12996/gmj.galenos.2023.3865 · Cited by 1
Wang, X., Dai, L., Wu, N., Wu, D., Wang, X., Meng, X., Zhang, Q., Lu, J., Yan, X., Zhang, J., et al. (2025) · MedComm · doi:10.1002/mco2.70156 · Cited by 1
Azmoun, S., Lewis, F. C., Shoieb, D., Jin, Y., Colicino, E., Mhatre‐Winters, I., Gu, H., Krishnamurthy, H. K., Richardson, J. R., Placidi, D., et al. (2025) · Brain Sciences · doi:10.3390/brainsci15080829 · Cited by 1
Alam, A., Ayaz, M., Zainab, Z., Ahmad, I., Elhenawy, A. A., Rehman, N. U., Ali, M., Al-Harrasi, A., & Ahmad, M. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.144352 · Cited by 1
Small noncoding RNAs: Pioneering a new therapeutic era in Alzheimer’s disease
Sahoo, S., Pattanaik, S., Kar, D. M., Prusty, S. K., & Sahu, P. K. (2025) · Gene · doi:10.1016/j.gene.2025.149827 · Cited by 1
Gortari, F., Rosero, M. T., Simison, C., Ottone, L., Rey, R. C., Aldecoa, M., Claverie, C. S., & Dorman, G. S. (2025) · Cureus · doi:10.7759/cureus.96097 · Cited by 1
Gavilán, J., Panes-Fernández, J., Araya, A., Pérez-Manríquez, C., Becerra, J., Varas, P., Moraga‐Cid, G., Yévenes, G. E., & Fuentealba, J. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1725284 · Cited by 1
Armstrong, T. D., Suwannasual, U., Stanley, A. H., Johnson, B., Youngblood, V., Santiago, I., Cook, M. (., Giasolli, S., & Lund, A. K. (2026) · Antioxidants · doi:10.3390/antiox15020161 · Cited by 1
Mazahir, F., Rahi, V., Kumar, A., Kaundal, R. K., & Yadav, A. K. (2026) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2026.102934 · Cited by 1
Ling, Z., Huang, S., Cheng, Y., Liu, X., Xu, X., Chen, Y., Hu, P., Wu, L., & Cai, G. (2026) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2026.100660 · Cited by 1
Anti-amyloid Monoclonal Antibodies in Alzheimer’s Disease: A New Hope
Nasibova, A. N., Khalilov, R. I., & Eftekhari, A. (2023) · International Journal of Aging · doi:10.34172/ija.2023.e21 · Cited by 1
Targeting Beta-Amyloid Protein with Monoclonal Antibodies: A New Hope for Alzheimer’s Treatment
Ashraf, F., Rasool, F. K., uddin, M. M. N., Siddiq, M. A., & Mustafa, M. S. (2023) · Annals of Neurosciences · doi:10.1177/09727531231190989 · Cited by 1
Dicyano-derivatives as mapping agents for peripheric Aβ plaques in Alzheimer’s disease mouse model
Yang, H., Zhou, C., Xu, G., Wang, T., Zhu, B., Lou, J., Li, X., Liu, X., & Yang, J. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101325 · Cited by 1
Alzheimer's disease: assessing the therapeutic potential of anti-Aβ (Beta-Amyloid) treatments
Almutairi, J. A. (2025) · Cellular and Molecular Biology · doi:10.14715/cmb/2025.70.1.12 · Cited by 1
Capabilities of combined therapy of Alzheimer’s disease
Васенина, Е. Е., Veryugina, N. I., & Levin, O. S. (2022) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202212211245 · Cited by 1
Exploring New Vista for Alzheimer's Disease Drug Targets (Part II)
Bolinger, A. A., & Zhou, J. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/156802662313230626121232 · Cited by 1
Six month repeat cognitive testing to identify people with MCI at greatest AD dementia riskPreprint
Tommet, D., Foldi, N. S., Lamar, M., Wang, C., Rabin, L. A., Grandoit, E., Choi, S., Jutten, R. J., Lee, M., Nakano, C. Y., et al. (2025) · medRxiv · doi:10.64898/2025.12.30.25343228 · Cited by 1
O’Malley, P. A. (2023) · Clinical Nurse Specialist · doi:10.1097/nur.0000000000000745
(2021) · Romanian Journal of Psychiatry & Psychotherapy · doi:10.37897/rjpp.2021.1.3
Kamikihito reduces β-amyloid25–35-induced axon damage via neurotrophic factors
Nagamatsu, T., Kubota, K., Watanabe, T., Katsurabayashi, S., & Iwasaki, K. (2023) · Journal of Natural Medicines · doi:10.1007/s11418-023-01761-3
Controlo de Biometais no Contexto de Fármacos Multifuncionais para a Doença de Alzheimer
Santos, M. A., & Chaves, S. (2024) · Boletim da Sociedade Portuguesa de Química · doi:10.52590/m3.p708.a30002748
Stowell, J. D., Mathers, J. C., Stanley, M. W., Aksakal, F. N. B., Aslett‐Bentley, A., Bánáti, D., Bobokhidze, E., Çatar, Ö. Ü., Dinç, Ö., Gvamichava, R., et al. (2024) · British Journal Of Nutrition · doi:10.1017/s0007114524000618
Age-related disease: Effective intervention
Fossel, M., & Cooke, J. P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15500-0.00013-x
Research Progress of Chemical Synthesis Drugs and Biotechnology Drugs for Alzheimer’s Disease
陈, 学. (2024) · Open Journal of Natural Science · doi:10.12677/ojns.2024.122051
Sharma, A., & Ewald, C. Y. (2023) · PubMed Central · doi:10.17912/micropub.biology.000907
Neurocognitive Disorders and Dementia
Weinberg, M., Chung, S. Y., Trinh, N., Chemali, Z. N., & Gatchel, J. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-11844-9.00017-5
Análise da eficácia clínica do fármaco Aducanumab no tratamento da Doença de Alzheimer
Turke, C. C., Neto, V. C., Zumbano, G. M., Shimada, T., Akamine, M. Y. E., Camargo, R. M., Morelli, S. D. A., & Estrela, H. F. G. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv7n3-115
Role of Efferocytosis in Health and Diseases
Abbasi, M. H., Shehzadi, N., Safdar, A., Aslam, R., Tariq, A., Shahid, M., Zafar, A., Sheikh, N., & Khawar, M. B. (2024) · Albus Scientia · doi:10.56512/as.2024.1.e240518
Суслов, Н. И., Сергеевна, Ф. Ю., & Коробов, М. Л. (2024) · Research Results in Pharmacology · doi:10.18413/rrpharmacology.10.489
Effectivity of Aβ Immunotherapies on Amyloid Plaque in Alzheimer’s Patients: A Close Examination
Tamilselvan, R., Kethar, J., & Varkey, J. (2024) · Journal of Student Research · doi:10.47611/jsrhs.v13i2.6649
Advances in Developing Small Molecule Drugs for Alzheimer's Disease
Zhang, W., Zhang, L., Lv, M., Fu, Y., Meng, X., Wang, M., & Wang, H. (2024) · Current Alzheimer Research · doi:10.2174/0115672050329828240805074938 · Cited by 1
The next chapter in Alzheimer's disease treatment
Theroux, J. D., Marino, A. B., & Drake, E. S. (2024) · The Nurse Practitioner · doi:10.1097/01.npr.0000000000000248
The Contribution of the Renin-Angiotensin System to Alzheimer’s Disease
Güzel, Ö., & Kehoe, P. G. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_525
Pharmacotherapy of Neurocognitive Disorders and Dementia
Weinberg, M. S., Chung, S. Y., Trinh, N., Chemali, Z. N., & Gatchel, J. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-11972-9.00015-6
Mundel, K. K., & Cooper, C. R. (2024) · Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · doi:10.26685/urncst.686
Murshid, N. M., Sahardi, N. F. N. M., & Makpol, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010241
Anticorpos anti-amiloide no tratamento da Doença de Alzheimer: uma revisão narrativa
Fonseca, B. S., Cordeiro, M. H. D. L., Abreu, P. H., & Takahashi, Y. (2025) · Revista Sociedade Científica · doi:10.61411/rsc202593118
Prosocial Intentions and Subsequent Cognitive Health: A Prospective Cohort Study
Farmer, J. G., Macchia, L., Bu, F., Gong, J., Steptoe, A., Demakakos, P., & Kubzansky, L. D. (2025) · The Journals of Gerontology Series B · doi:10.1093/geronb/gbaf004 · Cited by 1
Nutri Ayur in Cognition and Memory Dysfunction
Rahmatkar, S. N., Kumar, R., & Singh, D. (2025) · Springer eBooks · doi:10.1007/978-981-96-2960-2_9 · Cited by 1
Aamir, A., & Hafsa, H. (2025) · Neurology Letters · doi:10.61186/nl.4.1.42
Trends in Research on Gantenerumab for Alzheimer’s Disease: A Bibliometric and Thematic Analysis
Abdelwahab, S. İ., Taha, M. M. E., Alfaifi, H. A., Alzahrani, A. H., Aljahdali, I. A., Oraibi, O., Ali, S., Oraibi, B., Farasani, A. M., Jerah, A. A., et al. (2025) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273349645250324040257
fMRI in Neurodegenerative Diseases: From Scientific Insights to Clinical Applications
Dickerson, B. C., Canu, E., Tripodi, C., Agosta, F., & Filippi, M. (2025) · Neuromethods · doi:10.1007/978-1-0716-4438-6_24
Lynch, D. T., Agus, S., Kayed, R., Rasche, M., Samples, M., & Piccirella, S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.05.668780
Review on H3 Receptor Modulators: Future Pioneering approaches in Dementia Treatment
Bandaru, N., Shaikh, M. I., Yogendra, B. T., Krishna, W. S., & Rameshbhai, K. B. (2025) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/3219
Functional connectivity in neurodegenerative conditions
Basaia, S., Orlandi, F., Lumaca, L., Filippi, M., & Agosta, F. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-19099-5.00008-8
McDade, E., Cummings, J. L., Dhadda, S., Swanson, C. J., Reyderman, L., Kanekiyo, M., Koyama, A., Irizarry, M. C., Kramer, L. D., & Bateman, R. J. (2023) · Figshare · doi:10.6084/m9.figshare.22603849
Loraine, A., Farr, S. A., Niehoff, M. L., Larrea, I. G., Ganev, Y., Samanta, J., Rahman, K., Crider, A. M., Sandoval, K., & Witt, K. A. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103795
Shen, K., Liao, M., Hu, X., Li, P., Allgaier, J., Defante, A. P., & Lu, J. R. (2026) · Small Methods · doi:10.1002/smtd.202501717
Tirta, A. K. K., Jiantari, N. A., Dewi, F. N., Saepuloh, U., Rosmanah, L., & Darusman, H. S. (2026) · Acta Veterinaria Indonesiana · doi:10.29244/avi.14.1.90-95
Schinazi, V. R., Colombo, G., & Minta, K. (2026) · Springer eBooks · doi:10.1007/978-3-032-20563-6_15 · Cited by 1
Targeted cellular micropharmacies deliver therapeutic agents to the brain
Malviya, M., Baniya, S., Wong, E., Jain, T., Manoranjan, B., Vogt, K. C., Kehs, Z., Silberman, P. C., Dao, T., Li, Y., et al. (2026) · EMBO Molecular Medicine · doi:10.1038/s44321-026-00421-9
Re-Purposing a Rho-Associated Coiled-Coil Kinase (ROCK) Inhibitor for Alzheimer’s Disease
Cambi, X., Liu, Z., Guo, K., & Xia, W. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15093379
Does inflammatory bowel disease play a role in cognitive decline? A systematic review
Bertulli, A. M., Bezzio, C., Marsano, S., Corradini, I., Stranges, S., Matteoli, M., & Armuzzi, A. (2026) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjag057
Common biomarkers of Alzheimer disease and postoperative delirium
Fang, Y., Zhang, X., & Zhan, G. (2026) · Medicine · doi:10.1097/md.0000000000048921
Singh, V. B., Gupta, S., & Sella, R. N. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127043
Molecular Mechanisms of Neurodegenerative Diseases: Emerging Biomarkers and Therapeutic Targets
Yogi, S., & Singh, A. (2026) · Brain Sciences · doi:10.3390/brainsci16070675
Treatment Using Anti-Amyloid Antibodies for Alzheimer’s Disease
Chatterjee, S., Gayen, S., & Roy, S. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898815646126010012
Miaja, P., Martinez-Baños, M., Martín‐Bermejo, M. J., Moreno, I., Dominguez, M., & Bovolenta, P. (2026) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70301
Muhammad, N., Ai, R., Yang, L., Cui, Y., Wang, L., Weng, S., Wang, Y., Kakar, M. U., Khan, S., Ahmad, S., et al. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1877358 · Cited by 1
Novel 1,4-Diazepane derivatives as amyloid-beta (Aβ) aggregation inhibitors
Karuturi, R. C., Hefny, A. A., Shakeri, A., & Rao, P. P. N. (2026) · Frontiers in Chemistry · doi:10.3389/fchem.2026.1919936
Stangis, K. A., Pandey, R. S., Wang, A., Beck, J. S., Counts, S., Carter, G. W., & Park, K. H. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.28.747879
Acetylcholinergic therapy of Alzheimer’s disease and mixed dementia
Гришина, Д. А., Zakharov, V. V., & Борисовна, Л. А. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-279
Nam, M.-H., Park, H.-J., Hee-Yeon, L., Chen, Z.-Y., Yun, H.-D., Kim, Y., Lee, J.-Y., Shin, C.-H., Ha, J.-Y., & Seo, Y. (2026) · Neurotherapeutics · doi:10.1016/j.neurot.2026.e01077
Marimuthu, A., Singh, M. T., Balasubramanian, S., & Krishnamurthy, P. T. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06203-1
Nose-to-Brain Inorganic Nanosystems for Alzheimer’s Disease Theranostics
González-Pizarro, C., Vitta, Y., & Kogan, M. J. (2026) · Journal of Pharmaceutical and BioTech Industry · doi:10.3390/jpbi3040024
Zhu, Y., Jafari, Z., Kolb, B. E., & Mohajerani, M. H. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.107004
Matei, C., Palade, N. A., Dobri, A.-M., Dumitriu, D. O., Mutu, C., Popescu, A., Pintea, A. L., & Atasie, D. (2026) · Life · doi:10.3390/life16101749
BindingDB Entry 50019599: First-in-Class Selenium-Containing Potent Serotonin Receptor 5-HT
BindingDB (2024) · UC San Diego · doi:10.7270/q2n302bv
Metadata
- Authors
- Shi, M., Chu, F., Zhu, F., & Zhu, J.
- Affiliations
- First Hospital of Jilin University (CN)
- Shenzhen University (CN)
- Karolinska University Hospital (SE)
- Corresponding author
- Zhu, Feiqi
- Zhu, Jie
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2022-04-12
- Volume
- 14
- Pages
- 870517-870517
- ISSN
- 1663-4365 (ISSN-L)
- PMC
- PMC9039457
- OpenAlex
- W4223533048
- Cited by
- 275
- References
- 97
- Citations by year
- 2026: 28 · 2025: 66 · 2024: 104 · 2023: 68 · 2022: 8
- FWCI
- 8.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Aging Neuroscience (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- People's Government of Jilin Province
- Jilin University
- Sanming Project of Medicine in Shenzhen (SZSM201801014)
- First Hospital of Jilin University
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, anti-amyloid beta monoclonal antibody, aducanumab, lecanemab, amyloid plaques, disease-modifying therapy, immunotherapy, clinical trial results, adverse effects, amyloid-beta clearance, tau hyperphosphorylation, neurofibrillary tangles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
